Evotec SEEVO +1.11%64 Median PS Value is $15.93 as of Jun. 26, 2026, which is 1273% above its 10-year median of 1.16. GuruFocus rates EVO with a GF Score™ of 64/100 and a GF Value™ of $4.27 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 544 Drug Manufacturers companies, Evotec SE ranks better than 97.79% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Evotec SE's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $2.442. Evotec SE's 10-Year median PS Ratio is 6.5233. Therefore, the Median PS Value for today is $15.93.
As of today (2026-06-26), Evotec SE's share price is $2.74. Evotec SE's Median PS Value is $15.93. Therefore, Evotec SE's Price to Median PS Value for today is 0.17.
The historical rank and industry rank for Evotec SE's Median PS Value or its related term are showing as below:
EVO'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15 Med: 1.16 Max: 1.99
Current: 0.17
During the past 13 years, the highest Price to Median PS Value of Evotec SE was 1.99. The lowest was 0.15. And the median was 1.16.
EVO's Price-to-Median-PS-Value is ranked better than 97.79% of 544
companies
in the Drug Manufacturers industry
Industry Median: 0.83
vs EVO: 0.17
Evotec SE (NAS:EVO) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Evotec SE's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2.74
/
15.93
=
0.17
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE Median PS Value Related Terms
Evotec SE Median PS Value Historical Data
* Premium members only.
The historical data trend for Evotec SE's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EVO vs ZTS, UTHR, VTRS: Median PS Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Evotec SE's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 6.5233.
Evotec SE's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.442.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (EVO) has a Median PS Value of $15.93 as of Jun. 26, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Evotec SE and its competitors. This is 1273% above median its historical median of 1.16. Over the past decade, Evotec SE's Median PS Value has ranged from 0.15 to 1.99. According to the industry distribution chart, Evotec SE ranks #12 out of 544 companies in the Drug Manufacturers industry, placing it in the top 2.2%.
Is Evotec SE's Median PS Value too high?
Evotec SE's current Median PS Value of $15.93 is 1273% above median its 10-year median of 1.16. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 1.99. The Drug Manufacturers industry median Median PS Value is 0.83. Evotec SE's value of $15.93 is 1819.3% above this industry median. Based on the distribution chart, Evotec SE ranks #12 out of 544 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Evotec SE has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #12 out of 544 companies for Median PS Value. This places Evotec SE in the top 2% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.83. Evotec SE's value of $15.93 is 1819.3% above this benchmark. Historically, Evotec SE's own Median PS Value has ranged from 0.15 to 1.99 over the past decade. While the company's 10-year median is 1.16 vs. the industry median of 0.83, Evotec SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.83, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evotec SE's current Median PS Value of $15.93 is 1819.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current Median PS Value is $15.93, which is 1273% above median its own 10-year median of 1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (EVO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.27, compared to a current price of $2.74 — trading 35.8% below its estimated fair value. The current Median PS Value is $15.93, which is 1273% above median its 10-year median of 1.16 and 1819.3% above the Drug Manufacturers industry median of 0.83. Evotec SE's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Evotec SE (EVO), the current Median PS Value is $15.93 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (EVO) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of $2.74 is trading 35.8% below its estimated GF Value™ of $4.27.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for EVO:
Median PS Value: $15.93 (1273% above median its 10-year median of 1.16)
GF Value™: $4.27 vs. price of $2.74 (35.8% below fair value)
Industry Position: 1819.3% above the Drug Manufacturers median (#12 of 544)
No single metric tells the full story. See the EVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
64GF Score
Get the complete analysis for EVO
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVO has been successfully added to your 
